U.S. Electrical Stock News

In early May 2026, BorgWarner reported first‑quarter 2026 sales of US$3,533 million and net income of US$242 million, while maintaining full‑year guidance that targets net sales of US$14.00–US$14.30 billion and a U.S. GAAP operating margin of 9.7%–9.9%. A wave of recent program wins in electrified and emissions-focused technologies, spanning Asian eMotor awards and a Euro 7 commercial vehicle platform, suggests BorgWarner is deepening its role in next‑generation propulsion across both...

Recent performance and business snapshot Lantheus Holdings (LNTH) has drawn attention after a stretch of strong share price performance, with the stock up over the past week, month and past 3 months, while also showing a double digit 1 year total return. The company develops diagnostic and therapeutic products used in the detection and treatment of heart disease, cancer and other conditions, reporting revenue of US$1,546.178 million and net income of US$279.031 million from its portfolio of...

Why Marriott Vacations Worldwide (VAC) Is Back in Focus Marriott Vacations Worldwide (VAC) is back on investors’ radar after reporting first quarter 2026 results alongside higher full year contract sales guidance, reflecting a combination of mixed profitability and a more confident outlook for the rest of the year. See our latest analysis for Marriott Vacations Worldwide. VAC’s share price has climbed in recent months, with a 30 day share price return of 18.77% and a 90 day gain of 38.81%...

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...

MarketAxess Holdings (MKTX) is back in focus after first quarter 2026 earnings, reporting revenue of US$233.38 million and net income of US$77.88 million, alongside the completion of a US$300 million share repurchase program. See our latest analysis for MarketAxess Holdings. The earnings beat and new partnership with Moment come after a tougher stretch for holders, with the share price down 14.5% year to date and a 1 year total shareholder return of 31.41% in decline. This suggests sentiment...

In the first quarter of 2026, Flutter Entertainment reported sales of US$4,304 million, lower net income of US$218 million, and confirmed the completion of a US$1,241.88 million share buyback while announcing the departure of FanDuel CEO Amy Howe and expanded leadership roles for Christian Genetski and Dan Taylor. The combination of softer earnings, a leadership reshuffle at FanDuel, and continued capital returns via buybacks gives investors fresh information on how Flutter is balancing U.S...

Samsara (IOT) has attracted fresh attention after launching the Samsara Driver Cup, a nationwide competition that uses real-world driving data to recognize top U.S. professional drivers for safety, compliance, and fuel efficiency. See our latest analysis for Samsara. The Driver Cup launch comes as investors weigh a mixed picture, with a 90 day share price return of 18.45% contrasting with an 11.23% decline year to date and a 1 year total shareholder return decline of 30.65%, suggesting...

Gilat Satellite Networks (GILT) has attracted fresh attention after announcing two new orders: a multimillion contract with India based Nelco for its SkyEdge IV platform, and a separate US$7 million plus EnduroStream amplifier order linked to the U.S. Department of War. See our latest analysis for Gilat Satellite Networks. At a share price of US$18.84, the stock has had a 40.49% year to date share price return and a 188.96% 1 year total shareholder return. If these contract wins have you...

Vertex Pharmaceuticals (VRTX) is back in focus after Germany’s GKV-Spitzenverband agreed to reimburse CASGEVY, widening access to the gene edited therapy and reinforcing the company’s broader push beyond cystic fibrosis treatments. See our latest analysis for Vertex Pharmaceuticals. Despite strong Q1 results and reaffirmed full year guidance, recent momentum in Vertex’s share price has faded, with a 90 day share price return of an 11.07% decline, while the 5 year total shareholder return of...

Vaxcyte (PCVX) is back in focus after the company reported a first quarter net loss of US$320.62 million, along with updates on its advancing VAX-31 vaccine trials and an upcoming study for VAX-A1. See our latest analysis for Vaxcyte. The stock has given up some ground recently, with a 1 day share price return of 9.84% decline and a 30 day share price return of 15.18% decline. However, the year to date share price return is 10.8% and the 1 year total shareholder return is 63.69%, suggesting...

Ultragenyx Pharmaceutical: Recent Move in Context Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months. See our latest analysis for Ultragenyx Pharmaceutical. The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year...

Recent performance snapshot Spectrum Brands Holdings (SPB) has drawn attention after a mixed run in the stock, with a 7 day decline and a small drop in the latest session alongside positive returns over the month and past 3 months. Over longer periods, total return over the past year and past 3 years is positive, while the 5 year total return is slightly negative. This gives investors a mixed performance profile to weigh against the company’s fundamentals. See our latest analysis for Spectrum...

How BridgeBio Pharma stock has been trading BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date. See our latest analysis for BridgeBio Pharma. The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This...

Earnings, buyback and dividend set the stage for Healthcare Realty Trust Healthcare Realty Trust (HR) reported first quarter 2026 results, showing lower revenue than a year earlier alongside a much smaller net loss, while also completing a share repurchase tranche and affirming its quarterly dividend. See our latest analysis for Healthcare Realty Trust. The recent 13.1% 30 day share price return and 18.1% 90 day share price return suggest momentum has picked up, while the 1 year total...

In April 2026, Penske Automotive Group reported first-quarter 2026 results showing sales of US$7,657.8 million and net income of US$234.5 million, while also completing a long-running share repurchase program totaling 30,958,382 shares for US$2.32 billion since its 2010 authorization. The combination of softer year-over-year earnings and the completion of a buyback that has retired almost two-fifths of its shares reshapes how investors may weigh Penske’s capital returns against its current...

FedEx (FDX) is back in focus after expanding its work with ServiceNow to plug FedEx Dataworks logistics intelligence directly into ServiceNow’s procurement and supply chain platforms, creating data driven supplier and workflow tools. See our latest analysis for FedEx. Despite a 6.8% decline in the 7 day share price return and a small pullback today to US$375.93, FedEx still shows a 5.3% 30 day share price return and a 75.3% 1 year total shareholder return, which suggests that recent momentum...

Compass Minerals International (CMP) has just released its fiscal second quarter results, providing fresh data on profitability, segment margins, balance sheet activity and labor stability at a key mine operation. See our latest analysis for Compass Minerals International. The latest earnings release, return to quarterly net income and progress on debt reduction have come alongside a sharp turn in momentum. This includes a 42.2% year to date share price return and 57.24% 1 year total...

CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans. See our latest analysis for CVS Health. The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...

In the past week, OUTFRONT Media Inc. reported first-quarter 2026 results showing sales of US$429.6 million versus US$390.7 million a year earlier and a swing to net income of US$19.1 million, while also declaring a quarterly dividend of US$0.30 per share payable on June 30, 2026. This combination of revenue growth, a return to profitability, and a maintained cash dividend highlights improving operating performance and management’s confidence in the company’s cash generation. We’ll now...

Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions. See our latest analysis for Madrigal Pharmaceuticals. The share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...

Sana Biotechnology, Inc. recently drew attention with heavy pre-earnings options activity and elevated implied volatility, ahead of its first-quarter earnings release and its past May 12, 2026 presentation at the BofA Securities Healthcare Conference. Investors are closely watching how Sana’s engineered cell therapy pipeline, including its collaborations with Beam Therapeutics and Mayo Clinic, might feature in these updates. We’ll now examine how this heightened options activity ahead of...

Krystal Biotech recently reported first-quarter 2026 results, with net income rising to US$55.93 million and diluted EPS from continuing operations reaching US$1.83, and it also secured FDA approval for at-home use of Vyjuvek for dystrophic epidermolysis bullosa patients. These stronger earnings and expanded Vyjuvek administration options, alongside a high-profile appearance at the upcoming BofA Securities Health Care Conference, highlight how Krystal Biotech is pairing commercial progress...

Apollo Global Management (APO) has drawn attention after reporting record fee related earnings and crossing US$1 trillion in assets under management in the first quarter of 2026, alongside higher dividends and reaffirmed guidance. See our latest analysis for Apollo Global Management. The latest results and US$1 trillion AUM milestone come after a mixed price pattern, with a 21.29% 1 month share price return but a 12.84% decline year to date and a 2.58% 1 year total shareholder return. Recent...